Valuation: Agenus Inc.

Market Cap 315M 273M 256M 233M 439M 30.08B 446M 3.02B 1.18B 15.06B 1.18B 1.16B 50.22B P/E 2026 *
10.3x
P/E 2027 * -28.6x
Enterprise Value 315M 273M 256M 233M 439M 30.08B 446M 3.02B 1.18B 15.06B 1.18B 1.16B 50.22B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.29x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+1.45%
1 week-6.54%
Current month-6.67%
1 month+14.38%
3 months+101.73%
6 months+139.73%
Current year+122.93%
1 week 6.36
Extreme 6.36
7.2
1 month 4.66
Extreme 4.655
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
32
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 1994-03-30
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2021-10-31
Director TitleAgeSince
Chairman 73 2010-11-03
Director/Board Member 68 2007-03-07
Director/Board Member 68 2006-12-06
Date Insider Type Main position Quantity % Market Cap.
8/5/26 Free

Director

50,000 0.1117%
8/5/26 Free

Director

50,000 0.1117%
8/5/26 Free

Director

200,000 0.4469%
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%-6.54%+54.19%-74.07% 311M
+1.17%+1.09%+4.03%+15.74% 48.72B
-1.59%+2.12%+460.02%+573.56% 43.99B
-0.85%+7.95%+15.77%+80.09% 40.82B
-0.08%+3.91%+26.96%+9.86% 39.79B
0.00%+3.59%+20.51%+48.00% 32.7B
-3.61%-1.45% - - 16.84B
-2.52%-0.52%+24.35%+118.05% 16.66B
+0.72%+0.31%+4.94%+21.70% 13.95B
-1.09%+5.94%+81.46%+31.15% 13.58B
Average -0.64%+1.24%+76.92%+91.56% 26.74B
Weighted average by Cap. -0.59%+2.43%+97.48%+135.33%

Financials

2026 *2027 *
Net sales 140M 122M 114M 104M 196M 13.39B 199M 1.34B 524M 6.7B 527M 515M 22.36B 137M 119M 112M 102M 191M 13.11B 195M 1.31B 513M 6.56B 516M 504M 21.89B
Net income 35.2M 30.51M 28.6M 26.08M 49.07M 3.36B 49.86M 337M 131M 1.68B 132M 129M 5.61B -26.1M -22.62M -21.21M -19.34M -36.39M -2.49B -36.97M -250M -97.49M -1.25B -97.99M -95.87M -4.16B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
26-08-13 US$7.000 +1.45% 624,932
26-08-12 US$6.900 +1.02% 1,154,187
26-08-11 US$6.830 -2.43% 1,373,565
26-08-10 US$7.000 +0.57% 1,923,046
26-08-07 US$6.960 -7.08% 1,190,970
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.000USD
Average target price
19.50USD
Spread / Average Target
+178.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock